JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, vol.233, no.6, pp.742-752, 2021 (SCI-Expanded)
BACKGROUND: The aim of this randomized clinical trial was to evaluate the overall survival (OS) data of patients diagnosed with de novo stage IV breast cancer (BC) who received locoregional treatment (LRT) over a 10-year follow-up.